ANI Pharmaceuticals announced that it has acquired the NDAs and U.S. rights to market ATACAND, ATACAND HCT, ARIMIDEX, and CASODEX from AstraZeneca for $46.5 million in cash, royalties, and sales-based milestones.     AstraZeneca will continue to market and supply the products outside of the U.S. Collectively, these products generated approximately $19 million in U.S. market sales during the trailing twelve months through October 2017, according to IMS Health.   Arthur S. Przybyl,...